Mercury Labs

how big is Mercury Labs?

As of Jun 06, Mercury Laboratories Ltd has a market capitalization of 99.00 Cr, with recent net sales of 75.10 Cr and a net profit of 3.14 Cr over the last four quarters. Shareholder's funds are at 50.84 Cr, and total assets amount to 67.96 Cr.

As of Jun 06, Mercury Laboratories Ltd has a market capitalization of 99.00 Cr, categorizing it as a Micro Cap company.<BR><BR>As of Jun 06, the company's recent quarterly performance shows a sum of Net Sales for the latest 4 quarters at 75.10 Cr and a sum of Net Profit at 3.14 Cr. This data is based on Standalone financials.<BR><BR>As of Mar 24, the Standalone balance sheet snapshot indicates Shareholder's Funds at 50.84 Cr and Total Assets at 67.96 Cr.

Who are the top shareholders of the Mercury Labs?

The top shareholder of Mercury Labs is Shah Dilip Ramanlal Huf, holding 25.88%, with no pledged promoter holdings. The highest public shareholder is Rajeshri Ketan Shah at 2.2%, while individual investors collectively own 16.66%.

The top shareholders of Mercury Labs include the promoters, with Shah Dilip Ramanlal Huf holding the highest stake at 25.88%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Rajeshri Ketan Shah, who owns 2.2% of the shares. Additionally, individual investors collectively hold 16.66% of the company.

What does Mercury Labs do?

Mercury Laboratories Ltd is a Micro Cap pharmaceutical company established in 1962, specializing in medicinal drugs and formulations. As of March 2025, it reported net sales of 21 Cr and a net profit of 1 Cr, with a market cap of Rs 99 Cr.

Overview: <BR>Mercury Laboratories Ltd is engaged in the business of pharmaceutical items, medicinal drugs, and formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Mercury Laboratories Ltd started its business activities in 1962, converted into a Private Limited Company in February 1982, and later became a Limited Company in 1992 in Maharashtra. The most recent quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 21 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 99 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 27 <BR>Dividend Yield: 0.42% <BR>Debt-Equity: 0.06 <BR>Return on Equity: 5.86% <BR>Price to Book: 1.85<BR><BR>Contact Details: <BR>Address: 1st Floor 18 Shreeji Bhuwan 51, Princess Street Mangaladas Rd Mumbai Maharashtra : 400002 <BR>Tel: 91-22-66372841 <BR>Email: mllbrd@mwercurylabs.com <BR>Website: http://www.mercurylabs.com

Who are in the management team of Mercury Labs?

As of March 2023, the management team of Mercury Labs includes Rajendra R Shah (Executive Director), Dilip R Shah (Non-Executive Director), Divyakant Ramniklal Zaveri (Chairman & Independent Director), Bharat Dhirajlal Mehta (Independent Non-Executive Director), Paresh Mistry (Non-Executive & Non-Independent Director), and Janki Shah (Non-Executive Director). Each member contributes to the company's governance and strategic direction.

As of March 2023, the management team of Mercury Labs includes the following individuals:<BR><BR>1. Rajendra R Shah - Executive Director / Managing Director / Promoter<BR>2. Dilip R Shah - Non-Executive Director<BR>3. Divyakant Ramniklal Zaveri - Chairman & Independent Director<BR>4. Bharat Dhirajlal Mehta - Independent Non-Executive Director<BR>5. Paresh Mistry - Non-Executive & Non-Independent Director<BR>6. Janki Shah - Non-Executive Director<BR><BR>Each member plays a significant role in the governance and strategic direction of the company.

Has Mercury Labs declared dividend?

Yes, Mercury Laboratories Ltd has declared a 35% dividend, amounting to 3.5 per share, with an ex-date of September 20, 2024. While recent returns have been negative, the company has shown substantial growth over the longer term, particularly in the last 3 to 5 years.

Mercury Laboratories Ltd has declared a 35% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 35%<BR>- Amount per share: 3.5<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.42%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.67%, with a dividend return of 0%, resulting in a total return of -15.67%.<BR><BR>Over the past year, the price return was -6.41%, the dividend return was 0.40%, leading to a total return of -6.01%.<BR><BR>In the 2-year period, the price return was 0.13%, the dividend return was 0.84%, resulting in a total return of 0.97%.<BR><BR>For the 3-year period, the price return was 81.36%, with a dividend return of 2.44%, culminating in a total return of 83.8%.<BR><BR>In the last 4 years, the price return was 13.56%, the dividend return was 1.70%, leading to a total return of 15.26%.<BR><BR>Over the past 5 years, the price return was 85.27%, with a dividend return of 5.04%, resulting in a total return of 90.31%.<BR><BR>Overall, Mercury Laboratories Ltd has declared a significant dividend, and while recent returns over shorter periods have been negative, longer-term returns show substantial growth, particularly in the last 3 to 5 years.

Who are the peers of the Mercury Labs?

Mercury Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Makers Labs, Ind-Swift, Biofil Chemicals, and Achyut Healthcar. In terms of management risk, growth, and capital structure, Sun Pharma, Cipla, and Dr Reddy's Labs perform excellently, while Mercury Labs shows below-average growth and a 1-year return of -5.66%.

Peers: The peers of Mercury Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Makers Labs., Ind-Swift, Biofil Chemicals, and Achyut Healthcar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average management risk is found at Mercury Labs and Biofil Chemicals. Below Average management risk is seen at Makers Labs., Torrent Pharma, and Achyut Healthcar. For growth, Excellent growth is noted at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is present at Mercury Labs, Divi's Lab., Torrent Pharma, Makers Labs., Biofil Chemicals, and Achyut Healthcar. Excellent capital structure is held by Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Mercury Labs, while Below Average capital structure is seen at Makers Labs. and Achyut Healthcar, and Good capital structure is noted at Torrent Pharma and Biofil Chemicals.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Ind-Swift has the lowest at -19.94%. Mercury Labs' 1-year return is -5.66%, which is higher than Ind-Swift's but lower than the majority of its peers. Additionally, several peers, including Makers Labs., Ind-Swift, Biofil Chemicals, and Achyut Healthcar, have negative six-month returns.

What is the technical trend for Mercury Labs?

As of April 28, 2025, Mercury Labs exhibits a mildly bearish technical trend, influenced by mixed MACD signals and bearish daily moving averages.

As of 28 April 2025, the technical trend for Mercury Labs has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands and KST both reflect a mildly bearish outlook on the weekly and monthly time frames. The daily moving averages remain bearish, contributing to the overall mildly bearish sentiment. The Dow Theory suggests a mildly bearish trend on the weekly chart, with no clear trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and the bearish moving averages.

Is Mercury Labs overvalued or undervalued?

As of November 12, 2025, Mercury Labs is considered undervalued with an attractive valuation grade, featuring a PE Ratio of 21.55, an EV to EBITDA of 12.70, and a PEG Ratio of 0.93, which are favorable compared to peers like Sun Pharma and Divi's Lab, despite recent underperformance relative to the Sensex.

As of 12 November 2025, Mercury Labs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 21.55, an EV to EBITDA of 12.70, and a PEG Ratio of 0.93, indicating a favorable valuation compared to its growth prospects.<BR><BR>In comparison with peers, Mercury Labs' PE Ratio is significantly lower than that of Sun Pharma, which stands at 35.94, and Divi's Lab at 69.64, both classified as expensive. Other peers such as Cipla and Dr. Reddy's Labs have PE Ratios of 22.56 and 17.77, respectively, but still fall short of Mercury Labs' attractive valuation. Despite recent underperformance relative to the Sensex over the past year, the company's strong ratios suggest it is positioned well for future growth.

How has been the historical performance of Mercury Labs?

Mercury Labs has experienced mixed financial performance, with net sales and operating income peaking at 75.56 Cr in Mar'24 before declining to 75.10 Cr in Mar'25, while profitability metrics such as profit after tax and earnings per share significantly decreased. Despite an increase in total assets, cash flow from operations fell sharply, indicating financial challenges.

Answer:<BR>The historical performance of Mercury Labs shows a mixed trend in financial metrics over the years.<BR><BR>Breakdown:<BR>Mercury Labs' net sales have fluctuated slightly, with a peak of 75.56 Cr in Mar'24, followed by a slight decline to 75.10 Cr in Mar'25. Total operating income mirrored this trend, reaching 75.56 Cr in Mar'24 before decreasing to 75.10 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 66.52 Cr in Mar'24 to 68.08 Cr in Mar'25, impacting the operating profit, which fell from 9.04 Cr to 7.02 Cr in the same period. Profit before tax also declined from 6.92 Cr in Mar'24 to 4.66 Cr in Mar'25, leading to a decrease in profit after tax from 5.65 Cr to 3.14 Cr. The earnings per share (EPS) dropped significantly from 47.08 in Mar'24 to 26.17 in Mar'25. On the balance sheet, total assets increased from 67.96 Cr in Mar'24 to 74.24 Cr in Mar'25, while total liabilities also rose from 67.96 Cr to 74.24 Cr, indicating a growing debt level. Cash flow from operating activities decreased from 8.00 Cr in Mar'24 to 4.00 Cr in Mar'25, contributing to a net cash outflow of 6.00 Cr in Mar'25, compared to a neutral cash flow in the previous year. Overall, while Mercury Labs has shown growth in total assets, its profitability and cash flow have faced challenges in the latest fiscal year.

When is the next results date for Mercury Laboratories Ltd?

The next results date for Mercury Laboratories Ltd is 11 February 2026.

The next results date for Mercury Laboratories Ltd is scheduled for 11 February 2026.

Are Mercury Laboratories Ltd latest results good or bad?

Mercury Laboratories Ltd's latest results show strong year-on-year growth with a 185.29% increase in net profit and an 8.75% rise in net sales; however, sequential declines in both profit and sales raise concerns about sustainability and operational challenges, suggesting a cautious outlook for investors.

Mercury Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year increase in net profit, which surged by 185.29% to ₹0.97 crores in Q1 FY26, reflecting a recovery from a low base in the previous year. Additionally, net sales rose by 8.75% year-on-year to ₹18.14 crores. The operating margin also improved to 8.34%, up from 5.44% a year ago.<BR><BR>However, there are notable concerns. The sequential performance shows a decline, with net profit down 12.61% and net sales down 12.20% compared to the previous quarter. This raises questions about the company's operational momentum and ability to sustain growth. Furthermore, the operating margins remain volatile and significantly below the historical peak of 11.15% achieved in March 2024.<BR><BR>The company is also facing challenges with capital efficiency, as indicated by a return on equity (ROE) of just 10.12%, which is below the typical expectations for the pharmaceutical sector. Additionally, the absence of institutional investors and the company's consistent underperformance relative to its peers and the broader market are concerning signs.<BR><BR>Overall, while there are positive year-on-year growth metrics, the sequential declines and ongoing operational challenges suggest that the latest results may not be favorable in the broader context. Investors should approach with caution, considering the mixed signals from the financial performance.

Should I buy, sell or hold Mercury Laboratories Ltd?

Which are the latest news on Mercury Labs?

Why is Mercury Laboratories Ltd falling/rising?

As of 12-May, Mercury Laboratories Ltd's stock price is at 755.05, down 4.3% and underperforming against various moving averages and the sector. Despite increased investor participation, the overall sentiment remains bearish, with a year-to-date decline of 6.92%.

As of 12-May, Mercury Laboratories Ltd's stock price is falling, currently at 755.05, which reflects a decrease of 33.95 or 4.3%. The stock has been underperforming, having lost 5.5% over the last two days and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock opened with a significant loss of 4.28% today and reached an intraday low of 755.05. <BR><BR>In the context of broader market performance, the stock has also underperformed the sector by 2.81% today. Over the past week, the stock has declined by 1.23%, while the Sensex fell by 3.19%. Year-to-date, Mercury Laboratories Ltd has seen a decline of 6.92%, compared to a 12.51% drop in the Sensex. <BR><BR>Despite these negative trends, there has been a notable increase in investor participation, with delivery volume rising by 96.43% against the 5-day average on 11 May. However, the overall sentiment remains bearish, contributing to the stock's decline.